What is AbbVie's indefinite- lived intangible impairment?

AbbVie (ABBV) reported indefinite- lived intangible impairment of $94.80B in Q1 2026.

What does indefinite- lived intangible impairment mean?

The total value of identifiable intangible assets like brands or patents before accounting for wear and tear.

Indefinite- lived intangible impairment

AbbVie Indefinite- lived intangible impairment decreased by 0.1% to $94.80B in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementBalance Sheet Statement

SectionOther

CategoryMarket Position

SignalHigher is better

VolatilityStable

First reportedQ3 2025

Last reportedQ1 2026

How to read this metric

Growth indicates investment in intellectual property, brand equity, or customer relationships.

Detailed definition

The total gross carrying value of identifiable intangible assets, such as brands, customer lists, or software, excluding...

Peer comparison

Common in service-oriented and technology-heavy firms.

Metric ID: other_intangible_assets_gross_excluding_goodwill

Historical Data

2 periods

	Q4 '25	Q1 '26
Value	$94.87B	$94.80B
QoQ Change	—	-0.1%

Range$94.80B – $94.87B

Indefinite- lived intangible impairment at Other Companies

PfizerPFE View metric

Vertex PharmaceuticalsVRTX View metric

Gilead SciencesGILD View metric

Frequently Asked Questions

What is AbbVie's indefinite- lived intangible impairment?: AbbVie (ABBV) reported indefinite- lived intangible impairment of $94.80B in Q1 2026.
What does indefinite- lived intangible impairment mean?: The total value of identifiable intangible assets like brands or patents before accounting for wear and tear.